<DOC>
	<DOCNO>NCT01067521</DOCNO>
	<brief_summary>The study design assess efficacy Glatiramer Acetate ( GA ) injection 40 mg administer three time week compare placebo subject RRMS , measure number confirm relapse 12 month placebo control phase . The study two phase : - Placebo Controlled Phase : 12 month 40 mg administer three time week subcutaneous injection match placebo . - Open Label Extension : All subject continue treatment GA 40 mg administer three time week , dose strength commercially available treatment relapse remit multiple sclerosis ( RRMS ) patient development GA dose regimen stop Sponsor</brief_summary>
	<brief_title>A Study Subjects With Relapsing-Remitting Multiple Sclerosis ( RRMS ) Assess Efficacy , Safety Tolerability Glatiramer Acetate ( GA ) Injection 40 mg Administered Three Times Week Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Subjects must confirm documented MS diagnosis define Revised McDonald criterion relapsingremitting disease course . 2 . Subjects must ambulatory EDSS score 05.5 screen baseline visit . 3 . Subjects must relapsefree , stable neurological condition free corticosteroid treatment [ intravenous ( IV ) , intramuscular ( IM ) and/or per o ( PO ) ] ACTH 30 day prior screen ( month 1 ) screen baseline ( month 0 ) visit . 4 . Subjects must experience one following : At least one document relapse 12 month prior screen , At least two documented relapse 24 month prior screen , One document relapse 12 24 month prior screen least one document T1Gd enhance lesion MRI perform within 12 month prior screen . 5 . Subjects must 18 55 year age , inclusive . 6 . Women childbearing potential must practice acceptable method birth control . 7 . Subjects must able sign date write informed consent prior enter study . 8 . Subjects must willing able comply protocol requirement duration study 1 . Subjects progressive form MS. 2 . Use experimental investigational drug , and/or participation drug clinical study within 6 month prior screen . 3 . Use immunosuppressive ( include Mitoxantrone Fingolimod ) cytotoxic agent within 6 month prior screen visit . 4 . Use natalizumab ( Tysabri® ) monoclonal antibody within 2 year prior screen . 5 . Use cladribine within 2 year prior screen . 6 . Previous treatment immunomodulators ( include IFNβ 1a 1b , IV Immunoglobulin ( IVIg ) within 2 month prior screen . 7 . Previous use GA glatiramoid . 8 . Chronic ( 30 consecutive day ) systemic ( IV , PO IM ) corticosteroid treatment within 6 month prior screen visit . 9 . Previous total body irradiation total lymphoid irradiation . 10 . Previous stemcell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . 11 . Pregnancy breastfeed . 12 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical exam , ECG , abnormal laboratory test chest Xray . Such condition may include hepatic , renal metabolic disease , systemic disease , acute infection , current malignancy recent history ( 5 year ) malignancy , major psychiatric disorder , history drug and/or alcohol abuse allergy could detrimental accord investigator 's judgment . 13 . A known history sensitivity Gadolinium . 14 . Inability successfully undergo MRI scanning . 15 . A known drug hypersensitivity Mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Glatiramer Acetate</keyword>
</DOC>